Skip to content
Companies

BioStem Technologies

Placental tissue grafts for wound care

Raised to date

$5.5M

of $5.5M offered across 2 Form D filings

Investors
1
Last filed
Oct 9, 2026

About

BioStem Technologies is a regenerative medicine company that develops, manufactures, and commercializes allografts derived from perinatal (placental) tissue. It operates an AATB-accredited, FDA-registered facility running under cGMP standards in Pompano Beach, Florida. Its products are used primarily in chronic and acute wound care and in surgical applications. The company trades publicly and has announced a Nasdaq uplisting along with the acquisition of BioTissue Holdings' surgical and wound care business.

Its proprietary BioRetain processing method is designed to preserve the endogenous biological properties, structure, and matrix of fresh perinatal tissue rather than devitalizing it, which the company positions as a differentiator against conventionally processed amniotic allografts.

Funding

$3M, first sold Sep 2026$3M soldMay 2026Aug
Now
  • EquityFiled Oct 9, 2026Form D
    $3M/ $3M
  • EquityFiled Jun 3, 2026Form D
    $2.5M/ $2.5M

Product

VENDAJE

Human tissue allograft / wound care biologic

A placental-derived amniotic membrane allograft processed with BioStem's BioRetain method, applied as a wound covering in chronic and acute wound care.

  • Derived from donated human placental (perinatal) tissue
  • Processed using the proprietary BioRetain method to preserve tissue structure and endogenous growth factors
  • Manufactured in an AATB-accredited, FDA-registered, cGMP facility

Built for

Wound care clinics, hospitals, surgical centers, and physicians treating chronic and acute wounds

People on file